Emerging monoclonal antibodies and related agents for the treatment of chronic lymphocytic leukemia

Future Oncology

Volumn 9, Issue 1, 2013, Pages 69-91

  Robak, Tadeusz ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

alemtuzumab; CD20; CD37; CD40; inotuzumab ozogamicin; lucatumumab; moxetumomab pasudotox; obinutuzumab; ofatumumab; rituximab; TRU 016

Indexed keywords

BLINATUMOMAB; CHIR 12.12; DACETUZUMAB; EPRATUZUMAB; GALIXIMAB; HUMAX CD 20; LEXATUMUMAB; LUCATUMUMAB; LUMILIXIMAB; MAPATUMUMAB; MILATUZUMAB; MONOCLONAL ANTIBODY; OBINUTUZUMAB; OCARATUZUMAB; OCRELIZUMAB; OFATUMUMAB; UNCLASSIFIED DRUG; VELTUZUMAB;

ANEMIA; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; DOSE RESPONSE; DRUG BINDING; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTOPENIA; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD19; ANTIGENS, CD20; ANTIGENS, CD40; ANTIGENS, CD80; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOCONJUGATES; IMMUNOTOXINS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; TETRASPANINS;

EID: 84871499151     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.157     Document Type: Review

References (180)

1. Redaelli A, Laskin BL, Stephens JM et al. The clinical and epidemiological burden of chronic lymphocytic leukaemia. Eur. J. Cancer Care 13(3), 279-267 (2004).
2. CLL Trialists Collaborative Group. Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials. J. Natl Cancer Inst. 91(10), 861-868 (1999).
3. Robak T, Kasznicki M. Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 16(6), 1015-1027 (2002). (Pubitemid 34618840)
4. Robak T, Lech-Maranda E, Korycka A, Robak E. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: Mechanism of action and clinical activity. Curr. Med. Chem. 13(26), 3165-3189 (2006). (Pubitemid 44680862)
5. Trialists' Collaborative Group. Systematic review of purine analog treatment for chronic lymphocytic leukemia: Lessons for future trials. Haematologica 97(3), 428-436 (2012).
6. Robak T, Jamroziak K, Robak P. Current and emerging treatments for chronic lymphocytic leukaemia. Drugs 69(17), 2415-2449 (2009).
7. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 343(24), 1750-1757 (2000).
8. Robak T, Blonski JZ, Kasznicki M et al. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial. Blood 96(8), 2723-2729 (2000).
9. Eichhorst BF, Busch R, Hopfinger G et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 107(3), 885-891 (2006). (Pubitemid 43156283)
10. Robak T, Jamroziak K, Gora-Tybor J et al. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic oeukemia: A Phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).J. Clin. Oncol. 28(11), 1861-1869 (2010).
11. Robak T. Monoclonal antibodies in the treatment of chronic lymphoid leukemias. Leuk. Lymphoma 45(2), 205-219 (2004). (Pubitemid 38181421)
12. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8(1) 140-174 (2005).
13. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Expression of cell surface markers after human B lymphocyte activation. Proc. Natl Acad. Sci. USA 78(6), 3848-3852 (1981). (Pubitemid 11060476)
14. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin. Hematol. 47(2), 107-114 (2010).
15. Li H, Ayer LM, Lytton J, Deans JP. Store-operated cation entry mediated by CD20 in membrane rafts. J. Biol. Chem. 278(43), 42427-44234 (2003).
16. Manshouri T, Do KA, Wang X et al. Circulating CD20 is detectable in the plasma of patients with chromic lymphocytic leukemia and its prognostic significance. Blood 101(7), 2507-2513 (2003). (Pubitemid 36857605)
17. Robak T. Rituximab for chronic lymphocytic leukemia. Expert Opin Biol. Ther. 12(4), 503-515 (2012).
18. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs 12(Suppl. 2), S1-S4 (2001). (Pubitemid 32641719)
19. Zhou X, Hu W, Qin X. The role of complement in the mechanism of action of rituximab for B-cell lymphoma: Implications for therapy. Oncologist 13(9), 954-966 (2008).
20. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, Phase 3 trial. Lancet 376(9747), 1164-1174 (2010).
21. Robak T, Dmoszynska A, Solal-Celigny A et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 28(10), 1756-1765 (2010).
22. Bhat SA, Czuczman MS. Novel antibodies in the treatment of non-Hodgkin's lymphoma. Neth. J. Med. 67(8), 311-321 (2009).
23. Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr. Cancer Drug Targets 8(2), 156-171 (2008). (Pubitemid 351347252)
24. Boyd K, Dearden CE. Alemtuzumab in the treatment of chronic lymphocytic lymphoma. Expert Rev. Anticancer Ther. 8(4), 525-533 (2008). (Pubitemid 351818347)
25. Robak T. Alemtuzumab for B-cell chronic lymphocytic leukemia. Expert Rev. Anticancer Ther. 8(7), 1033-1051 (2008).
26. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 332(6162), 323-327 (1988). (Pubitemid 18091075)
27. Hale G. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology 1(3-4), 175-187(1995). (Pubitemid 3018374)
28. Rao SP, Sancho J, Campos-Rivera J et al. Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis. PLoS One 7(6), e39416 (2012).
29. Stilgenbauer S, Dohner H. Campath-1H induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N. Engl. J. Med. 347(6), 452-453 (2002). (Pubitemid 34851846)
30. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25(35), 5616-5623 (2007).
31. Elter T, Gercheva-Kyuchukova L, Pylylpenko H et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: A randomised Phase 3 trial. Lancet Oncol. 12(13), 1204-1213 (2011).
32. Demko S, Summers J, Keegan P, Pazdur R. FDA drug approval summary: Alemtuzumab as single-agent treatment for B-cell chronic lymphocytic leukemia. Oncologist 13(2), 167-174 (2008). (Pubitemid 351342581)
33. Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies. Bio. Drugs 25(1), 13-25 (2011).
34. Lim SH, Beers SA, French RR et al. Anti- CD20 monoclonal antibodies: Historical and future perspectives. Haematologica 95(1), 135-143 (2010).
35. van Meerten T, Hagenbeek A. CD20-targeted therapy: The next generation of antibodies. Semin. Hematol. 47(2), 199-210 (2010).
36. Robak T. Ofatumumab, a human monoclonal antibody for lymphoid malignancies and autoimmune disorders. Curr. Opin Mol. Ther. 10(3), 294-309 (2008). (Pubitemid 351799281)
37. Teeling JL, Mackus WJ, Wiegman LJ et al. The of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177(1), 362-371 (2006). (Pubitemid 43939148)
38. Beum PV, Lindorfer MA, Beurskens F et al. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis. J. Immunol. 181(1), 822-832 (2008).
39. Coiffier B, Lepretre S, Pedersen LM et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. A Phase I-II study. Blood 111(3), 1094-1100 (2008). (Pubitemid 351213387)
40. Wierda WG, Kipps TJ, Mayer J et al. Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J. Clin. Oncol. 28(10), 1749-1755 (2010).
41. Wierda WG, Padmanabhan S, Chan GW et al. Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: Results from the Phase 2 international study. Blood 118(19), 5126-5129 (2011).
42. Wierda WG, Kipps TJ, Dürig J et al. Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 117(24), 6450-6458 (2011).
43. Lemery SJ, Zhang J, Rothmann MD et al. US Food and Drug Administration approval: Ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin. Cancer Res. 16(17), 4331-4338 (2010).
44. Gravanis I, Ersbøll J, Skovlund E et al. Medicines Agency review of ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukemia in patients refractory to fludarabine and alemtuzumab: Summary of the scientific assessment of the European medicines agency committee for medicinal products for human use. Oncologist 15(12), 1335-1343 (2010).
45. Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr. Opin Investig. Drugs 9(11), 1206-1215 (2008).
46. Kausar F, Mustafa K, Sweis G et al. Ocrelizumab: A step forward in the evolution of B-cell therapy. Expert Opin Biol. Ther. 9(7), 889-895 (2009).
47. Morschhauser F, Marlton P, Vitolo U et al. Results of a Phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma. Ann. Oncol. 21(9), 1870-1876 (2010).
48. Goldenberg DM, Rossi EA, Stein R et al. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 113(5), 1062-1070 (2009).
49. Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti- CD20 monoclonal antibody): Characterization, current clinical results, and future prospects. Leuk. Lymphoma 51(5), 747-755 (2010).
50. Morschhauser F, Leonard JP, Fayad L et al. Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non- Hodgkin's lymphoma: Phase I/II results. J. Clin. Oncol. 27(20), 3346-3353(2009).
51. Negrea GO, Elstrom R, Allen SL et al. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma. Haematologica 96(4), 567-573 (2011).
52. Owen C, Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol. Ther. 12(3), 343-351 (2012).
53. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr. Opin Investig. Drugs 10(6), 588-596 (2009).
54. Mössner E, Brünker P, Moser S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 115(22), 4393-4402 (2010).
55. Illidge TM. Obinutuzumab (GA101) - a different anti-CD20 antibody with great expectations. Expert Opin. Biol. Ther. 12(5), 343-335 (2012).
56. Salles G, Morschhauser F, Lamy T et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood 119(22), 5126-5132 (2012).
57. Sehn LH, Assouline SE, Stewart DA et al. A Phase I study of obinutuzumab induction followed by two years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood 119(22), 5118-5125 (2012).
58. Bowles JA, Wang SY, Link BK et al. CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 108(8), 2648-2654 (2006).
59. Forero-Torres A, de Vos S, Pohlman BL et al. Results of a Phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgRIIIa-genotyped patients with previously treated follicular lymphoma. Clin. Cancer Res. 18(5), 1395-1403 (2012).
60. Jasper GA, Arun I, Venzon D et al. Variables affecting the quantitation of CD22 in neoplastic B cells. Cytometry B Clin. Cytom. 80(2), 83-90 (2011).
61. Nitschke L. The role of CD22 and other inhibitory co-receptors in B-cell activation. Curr. Opin Immunol. 17(3) 290-297 (2005). (Pubitemid 40692664)
62. Tedder TF, Poe JC, Haas KM. CD22: A multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv. Immunol. 88, 1-50 (2005). (Pubitemid 41439747)
63. Nitschke L. CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions. Immunol. Rev. 230(1), 128-143 (2009).
64. Leonard JP, Coleman M, Ketas JC et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non- Hodgkin's lymphoma. J. Clin. Oncol. 21(16), 3051-3059 (2003). (Pubitemid 46606284)
65. Carnahan J, Stein R, Qu Z et al. Epratunuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol. Immunol. 44(6), 1331-1341 (2007). (Pubitemid 44415959)
66. Carnahan J, Wang P, Kendall R et al. Epratuzumab, a humanized monoclonal antibody targeting CD22: Characterization of in vitro properties. Clin. Cancer Res. 9(Suppl.), 3982-3990 (2003).
67. Leonard JP, Coleman M, Ketas JC et al. Epratuzumab, a humanized anti CD-22 antibody, in aggressive non-Hodgkin's lymphoma: Phase I/II clinical trial results. Clin. Cancer Res. 10(16), 5327-5334 (2004). (Pubitemid 39100467)
68. Pathan NI, Chu P, Hariharan K et al. Mediation of apoptosis by and anti-tumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood 111(3), 1594-1602 (2008). (Pubitemid 351213450)
69. Beavil AJ, Edmeades RL, Gould HJ, Sutton BJ. a-helical coiled-coil stalks in the low-affinity receptor for IgE (FceRII/CD23) and related C-type lectins. Proc. Natl Acad. Sci. USA 89(2), 753-757 (1992).
70. Lemieux GA, Blumenkron F, Yeung N et al. The low affinity IgE receptor (CD23) is cleaved by the metalloproteinase ADAM10. J. Biol. Chem. 282(20), 14836-14844 (2007). (Pubitemid 47093331)
71. Fournier S, Tran ID, Suter U, Biron G, Delespesse G, Sarfati M. The in vivo expression of type B CD23 mRNA in B-chronic lymphocytic leukemic cells is associated with an abnormally low CD23 upregulation by IL-4: Comparison with their normal cellular counterparts. Leuk. Res. 15(7), 609-618 (1991).
72. Fournier S, Yang LP, Delespesse G, Rubio M, Biron G, Sarfati M. The two CD23 isoforms display differential regulation in chronic lymphocytic leukaemia. Br. J. Haematol. 89(2), 373-379 (1995).
73. Acharya M, Borland G, Edkins AL et al. CD23/FceRII: Molecular multi-tasking. Clin. Exp. Immunol. 162(1), 12-23 (2010).
74. Byrd JC, O'Brien S, Flinn IW et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin. Cancer Res. 13(15 Pt 1), 4448-4455 (2007). (Pubitemid 47219713)
75. Byrd JC, Kipps TJ, Flinn IW et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 115(3), 489-495 (2010).
76. Robak T. Improving FCR immunochemotherapy in CLL. Blood 115(3), 437-438 (2010).
77. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 116(19), 3705-3714 (2010).
78. Stein R, Mattes MJ, Cardillo TM et al. CD74: A new candidate target for the immunotherapy of B-cell neoplasms. Clin. Cancer Res. 13(18 Pt 2), 5556-5563 (2007).
79. Starlets D, Gore Y, Binsky I et al. Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107(12), 4807-4816 (2006). (Pubitemid 43882632)
80. Gupta P, Goldenberg DM, Rossi EA et al. Dual-targeting immunotherapy of lymphoma: Potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas. Blood 119(16), 3767-3778 (2012).
81. Shachar I, Haran M. The secret second life of an innocent chaperone: The story of CD74 and B cell/chronic lymphocytic leukemia cell survival. Leuk. Lymphoma 52(8), 1446-1454 (2011).
82. Mark T, Martin P, Leonard JP, Niesvizky R. Milatuzumab: A promising new agent for the treatment of lymphoid malignancies. Expert Opin Investig. Drugs 18(1), 99-104 (2009).
83. Sapra P, Stein R, Pickett J et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU- 110, in a human multiple myeloma xenograft and in monkeys. Clin. Cancer Res. 11(14), 5257-5264 (2005). (Pubitemid 41003714)
84. Chang CH, Sapra P, Vanama SS, Hansen HJ, Horak ID, Goldenberg DM. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 106(13), 4308-4314 (2005). (Pubitemid 41775941)
85. Alinari L, Mahoney E, Patton J et al. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death. Blood 118(26), 6893-6903 (2011).
86. Alinari L, Yu B, Christian BA et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood 117(17), 4530-4541 (2011).
87. Christian B, Alinari L, Earl CT et al. A Phase I study of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, in patients with relapsed and refractory B-cell non- Hodgkin's lymphoma. Presented at: 53rd ASH Annual Meeting and Exposition. San Diago, CA, USA, 10-13 December 2011.
88. Schattner EJ. CD40 legend in CLL pathogenesis and therapy. Leuk. Lymphoma 37(5-6), 461-472 (2000). (Pubitemid 30219055)
89. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kB activity and apoptosis in chronic lymphocytic leukemia B cells. J. Immunol. 164(4), 2200-2206 (2000). (Pubitemid 30108780)
90. Cuni S, Perez-Aciego P, Perez-Chacon G. A sustained activation of PI3K/NF-kB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 18(8), 1391-1400 (2004). (Pubitemid 39136749)
91. Ullenhag G, Loskog AS. AdCD40L - crossing the valley of death? Int. Rev. Immunol. 31(4), 289-298 (2012).
92. Luqman M, Klabunde S, Lin K et al. The antileukemia activity of a human anti- CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 112(3), 711-720 (2008).
93. Byrd JC, Kipps TJ, Flinn IW et al. Phase 1 study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk. Lymphoma 53(11), 2136-2142 (2012).
94. Khubchandani S, Czuczman MS, Hernandez- Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr. Opin Investig. Drugs 10(6), 579-587(2009).
95. Law CL, Gordon KA, Collier J et al. Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 65(18), 8331-8339 (2005).
96. Advani R, Forero-Torres A, Furman RR et al. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 27(26), 4371-4377 (2009).
97. Furman RR, Forero-Torres A, Shustov A, Drachman JG. A Phase I study of dacetuzumab (SGN-40, a humanized anti- CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 51(2), 228-235 (2010).
98. Horton HM, Bernett MJ, Peipp M et al. Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies. Blood 116(16), 3004-3012 (2010).
99. Hock BD, Starling GC, Patton WN et al. Identification of a circulating soluble form of CD80: Levels in patients with hematological malignancies. Leuk. Lymphoma 45(10), 2111-2118 (2004). (Pubitemid 39232862)
100. Dakappagari N, Ho SN, Gascoyne RD, Ranuio J, Weng AP, Tangri S. CD80 (B7.1) is expressed on both malignant B cells and nonmalignant stromal cells in non-Hodgkin lymphoma. Cytometry B. Clin. Cytom. 82(2), 112-119 (2012).
101. Chaperot L, Plumas J, Jacob MC et al. Functional expression of CD80 and CD86 allows immunogenicity of malignant B cells from non-Hodgkin's lymphomas. Exp. Hematol. 27(3), 479-488 (1999). (Pubitemid 29125056)
102. Suvas S, Singh V, Sahdev S et al. Distinct role of CD80 and CD86 in the regulation of the activition of B-cell and B-cell lymphoma. J. Biol. Chem. 277(10), 7766-7775 (2002). (Pubitemid 34968223)
103. Curiel TJ, Wei S, Dong H et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 9(5), 562-567 (2003). (Pubitemid 36597102)
104. Park JJ, Omiya R, Matsumura Y et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116(8), 1291-1298 (2010).
105. Mir MA, Agrewala JN. Signaling through CD80: An approach for treatinglymphomas. Expert Opin Ther. Targets 12(8), 969-979 (2008).
106. Bhat S, Czuczman MS. Galiximab: A review. Expert Opin Biol. Ther. 10(3), 451-458 (2010).
107. Vinjamaram S, Czuczman MS, Hernandez- Ilizaliturri FJ. The use of galiximab in non- Hodgkin lymphoma. Clin. Lymphoma Myeloma 8(5), 277-282 (2008).
108. Hariharan K, Anderson D, Leigh B et al. Therapeutic activity of IDEC-114 (anti- CD80) and rituximab (Rituxan) in B cell lymphoma. Blood 98(Suppl. 1), S2549 (2001) (Abstract).
109. Czuczman MS, Thall A, Witzig TE et al. Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J. Clin. Oncol. 23(19), 4390-4398 (2005). (Pubitemid 46207013)
110. Leonard J, Friedberg J, Younes A et al. A Phase I/II study of galiximab (an anti- CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory follicular lymphoma. Ann. Oncol. 18(7), 1216-1223 (2007). (Pubitemid 47244369)
111. Czuczman MS, Leonard JP, Jung S et al. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Ann. Oncol. 23(9), 2356-2362. (2012).
112. Moldenhauer G. CD37. J. Biol. Regul. Homeost. Agents 14(4), 281-283 (2000).
113. Flinn IW. CD37: The comeback kid. Blood 118(15), 4007-4008 (2011).
114. Lapalombella R, Yeh YY, Wang L et al. Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21(5) 694-708 (2012).
115. Jones EL, Demaria MC, Wright MD. Tetraspanins in cellular immunity. Biochem. Soc. Trans. 39(2), 506-511 (2011).
116. Heider KH, Kiefer K, Zenz T et al. A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 118(15), 4159-4168 (2011).
117. Belov L, de la Vega O, dos Remedios CG, Mulligan SP, Christopherson RI. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res. 61(11), 4483-4489 (2001). (Pubitemid 32685778)
118. Fearon DT, Carroll MC. Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu. Rev. Immunol. 18, 393-422 (2000). (Pubitemid 30365386)
119. Hammer O. CD19 as an attractive target for antibody-based therapy. MAbs 4(5), 571-577 (2012).
120. Gerber HP, Kung-Sutherland M, Stone I et al. Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood 113(18), 4352-4361 (2009).
121. Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of T cell engaging antibody. Science 321(5891), 974-977 (2008).
122. Nagorsen D, Bargou R, Ruttinger D et al. Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab. Leuk. Lymphoma 50(6), 8868-8891 (2009).
123. Viardot A, Goebeer M, Sheele JS et al. Treatment of patients with non-Hodgkin lymphoma (NHL) with CD19/CD3 bispecific antibody blinatumomab (MT103): Double-step dose increase to continuous infusion of 60ug /m2/d is tolerable and highly effective. Blood 116, 1186 Abstract 2880 (2010).
124. Horton HM, Bernett MJ, Pong E et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 68(19), 8049-8057 (2008).
125. Awan FT, Lapalombella R, Trotta R et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 115(6), 1204-1213 (2010).
126. Zalevsky J, Leung IW, Karki S et al. The impact of Fc engineering on an anti-CD19 antibody: Increased Fcg receptor affinity enhances B-cell clearing in nonhuman primates. Blood 113(16), 3735-3743 (2009).
127. Humphreys RC, Halpern W. TRAIL receptors: Targets for cancer therapy. Adv. Exp. Med. Biol. 615, 127-158 (2008).
128. Xiao W, Ishdorj G, Sun J, Johnston JB, Gibson SB. Death receptor 4 is preferentially recruited to lipid rafts in chronic lymphocytic leukemia cells contributing to tumor necrosis related apoptosis inducing ligand-induced synergistic apoptotic responses. Leuk. Lymphoma 52(7), 1290-1301 (2011).
129. Yerbes R, Palacios C, López-Rivas A. The therapeutic potential of TRAIL receptor signalling in cancer cells. Clin. Transl Oncol. 13(12), 839-847 (2011).
130. Luster TA, Carrell JA, McCormick K, Sun D, Humphreys R. Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol. Cancer Ther. 8(2), 292-302 (2009).
131. Plummer R, Attard G, Pacey S et al. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res. 13(20), 6187-6194 (2007). (Pubitemid 350075080)
132. Pukac L, Kanakaraj P, Humphreys R et al. HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumors types in vitro and in vivo. Br. J. Cancer 92(8), 1430-1441 (2005). (Pubitemid 40705010)
133. Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD 20. Clin. Cancer Res. 13(15 Pt 1), 4556-4564 (2007). (Pubitemid 47219726)
134. Younes A, Vose JM, Zelenetz AD et al. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non- Hodgkin's lymphoma. Br. J. Cancer 103(12), 1783-1787 (2010).
135. Natoni A, MacFarlane M, Inoue S et al. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br. J. Haematol. 139(4), 568-577 (2007). (Pubitemid 350043817)
136. Wakelee HA, Patnaik A, Sikic BI et al. Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann. Oncol. 21(2), 376-381 (2010).
137. Burge DJ, Bookbinder SA, Kivitz AJ et al. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: A Phase I, open-label, dose-escalation clinical study. Clin. Ther. 30(10), 1806-1816 (2008).
138. Hayden-Ledbetter MS, Cerveny CG, Espling E et al. CD20-directed small modular immunopharmaceutical, TRU-015, depletes normal and malignant B cells. Clin. Cancer Res. 15(8), 2739-2746 (2009).
139. Nickerson-Nutter C, Tchistiakova L, Seth NP et al. Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys. Rheumatology 50(6), 1033-1044 (2011).
140. Zhao X, Lapalombella R, Joshi T et al. Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110(7), 2569-2577 (2007). (Pubitemid 47527052)
141. Robak T, Robak P, Smolewski P. TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies. Curr. Opin Investig. Drugs 10(12), 1383-1390 (2009).
142. Furman RR, Andritos L, Flinn IW et al. Phase 1 dose escalation study of TRU-016, an anti-CD37 SMIPTM protein in relapsed and refractory CLL. Blood 116(Suppl.), S31 (Abstract 56) (2010).
143. Baum PR, Cerveny C, Gordon B et al. Evaluation of the effect of TRU-16, an anti- CD37 directed SMIP in combination with other therapeutic drugs in models of non- Hodgkin's lymphoma. J. Clin. Oncol. 27(15), Abstract 8571 (2009).
144. Andritsos L, Furman RR, Flinn IW et al. A Phase 1 trial of TRU-016, an anti-CD37 small modular immunopharmaceutical (SMIPTM) protein in relapsed and refractory CLL: Early promising clinical activity. Blood 114(22), 3124a (2009).
145. Casi G, Neri D. AntibodyYdrug conjugates: Basic concepts, examples and future perspectives. J. Control. Release 161(2), 422-428 (2012).
146. Polakis P. Arming antibodies for cancer therapy. Curr. Opin Pharmacol. 5(4), 382-387 (2005). (Pubitemid 40932040)
147. Hans K Erickson, Wayne C Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody maytansinoid conjugates Bioconjugate Chem. 21(1), 84-92 (2010).
148. Ricart AD, Tolcher AW. Technology insight: Cytotoxic drug immunoconjugates for cancer therapy. Nat. Clin. Pract. Oncol. 4(4), 245-255 (2007). (Pubitemid 46510534)
149. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin treatment of cancer. Annu. Rev. Med. 58(1), 221-237 (2007). (Pubitemid 46706511)
150. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat. Rev. Cancer 6(7), 559-565 (2006). (Pubitemid 43980544)
151. Manoukian G, Hagemeister F. Denileukin diftitox: A novel immunotoxin. Expert Opin Biol. Ther. 9(11), 1445-1451 (2009).
152. Lansigan F, Stearns DM, Foss F. Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma. Cancer Manag. Res. 5(2), 53-59 (2010).
153. Frankel AE, Fleming DR, Hall PD et al. A Phase II study of DT fusion protein denileukin diftitox in patients with fludarabine-refractory chronic lymphocytic leukemia. Clin. Cancer Res. 9(10 Pt 1), 3555-3561 (2003). (Pubitemid 37169218)
154. Frankel AE, Surendranathan A, Black JH et al. Phase II clinical studies of denileukin diffitox fusion protein in patients with previously treated chronic lymphocytic leukemia. Cancer 106(10), 2158-2164 (2006). (Pubitemid 43673237)
155. Ansell SM, Tang H, Kurtin PJ et al. Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphoma. Leukemia 26(5), 1046-1052 (2012).
156. Wong BY, Dang NH. Inotuzumab ozogamicin as novel therapy in lymphomas. Expert Opin Biol. Ther. 10(8), 1251-1258 (2010).
157. Takeshita A, Shinjo K, Yamakage N et al. CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: Analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. Br. J. Haematol. 146(1), 34-43 (2009).
158. DiJoseph JF, Dougher MM, Kalyandrug LB et al. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non- Hodgkin's B-cell lymphoma. Clin. Cancer Res. 12(1), 242-249 (2006). (Pubitemid 43166200)
159. de Vries JF, Zwaan CM, De Bie M et al. The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC- 544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 26(2), 255-264 (2012).
160. Advani A, Coiffier B, Czuczman MS et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: Results of a Phase I study. J. Clin. Oncol. 28(12), 2085-2093 (2010).
161. Kantarjian H, Thomas D, Jorgensen J et al. Inotuzumab ozogamicin, an anti-CD22Y calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: A Phase 2 study. Lancet Oncol. 13(4), 403-411 (2012).
162. Ogura M, Hatake K, Ando K et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 103(5), 933-938 (2012).
163. Kreitman RJ, Wilson WH, Bergeron K et al. Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. 345(4), 241-247 (2001). (Pubitemid 32695063)
164. Kreitman RJ, Pastan I. Antibody fusion proteins: Anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 17(20), 6398-6405 (2011).
165. Kreitman RJ, Tallman MS, Robak T et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J. Clin. Oncol. 30(15), 1822-1828 (2012).
166. Polson AG, Ho WY, Ramakrishnan V. Investigational antibodyYdrug conjugates forhematological malignancies. Expert Opin Investig. Drugs 20(1), 75-85 (2011).
167. Stephan JP, Chan P, Lee C et al. Anti-CD22Y MCCYDM1 and MCYMMAF conjugates: Impact of assay format on pharmacokinetic parameters determination. Bioconjug. Chem. 19(8), 1673-1683 (2008).
168. Polson AG, Williams M, Gray AM et al. Anti-CD22-MCCYDM1: An antibodyYdrug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 24(9), 1566-1573 (2010).
169. Blanc V, Bousseau1 A, Caron A et al. SAR3419: An anti-CD19-maytansinoid immunoconjugate for the treatment of B-cell malignancies. Clin. Cancer Res. 17(20), 6448-6458 (2011).
170. Lutz RJ, Zuany-Amorim C, Vrignaud P et al. Preclinical evaluation of SAR3419 (huB4- DM4), an anti-CD19-maytansinoid immunoconjugate, for the treatment of B-cell lymphoma. Proc. Am. Assoc. Cancer Res. 47, Abstract 3731 (2006).
171. Younes A, Gordon L, Kim S et al. Phase I multi-dose escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous (IV) infusion every 3 weeks to patients with relapsed/ refractory B-cell non-Hodgkin's lymphoma (NHL).Blood 112(243) Abstract 585 (2009).
172. Coiffier B, Ribrag V, Dupuis J et al. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL).J. Clin. Oncol. 29(Suppl.), Abstract 8017 (2011).
173. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibodyYdrug conjugates. Cancer Res. 71(20), 6300-6309 (2011).
174. Barta SK, Zou Y, Schindler J et al. Synergy of sequential administration of a deglycosylated ricin A chain-containingm combined anti- CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia. Leuk. Lymphoma 53(10), 1999-2003 (2012).
175. Herrera L, Farah RA, Pellegrini VA et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 14(5), 853-858 (2000). (Pubitemid 30235063)
176. Ghetie MA, Tucker K, Richardson J, Uhr JW, Vitetta ES. The antitumor activity of an anti- CD22 immunotoxin in SCID mice with disseminated Daudi lymphoma is enhanced by either an anti-CD19 antibody or an anti-CD19 immunotoxin. Blood 80(9), 2315-2320 (1992).
177. Herrera L, Bostrom B, Gore L et al. A Phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J. Pediatr. Hematol. Oncol. 31(12), 936-941 (2009).
178. Schindler J, Gajavelli S, Ravandi F et al. A Phase I study of a combination of anti- CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br. J. Haematol. 154(4), 471-476 (2011).
179. Messmann RA, Vitetta ES, Headlee D et al. A Phase I study of combination therapy with immunotoxins IgGYHD37-deglycosylated ricin A chain (dgA) and IgGYRFB4-dgA (Combotox) in patients with refractory CD19+, CD22+ B cell lymphoma. Clin. Cancer Res. 6(4), 1302-1313 (2000). (Pubitemid 30226212)
180. Vallera DA, Chen H et al. Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk. Res. 33(9), 1233-1242 (2009).